Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Theophylline
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Recipient : Cyrano Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Kyorin & Cyrano Sign Option Deal for CYR-064 in Post-Viral Smell Loss
Details : Under the agreement, KYORIN obtains an option for the license of the right to develop and commercialize CYR-064. It is being evaluated for the treatment of hyposmia.
Product Name : CYR-064
Product Type : Plant Extract/Herbal
Upfront Cash : Undisclosed
February 18, 2025
Lead Product(s) : Theophylline
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Recipient : Cyrano Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : KYORIN will grant Sumitomo Pharma the exclusive rights to develop, manufacture, and commercialize the therapeutic agent for OAB called Vibegron in in Taiwan and Other Asian Countries, and Sumitomo Pharma will develop, manufacture, and commercialize the C...
Product Name : Gemtesa
Product Type : Small molecule
Upfront Cash : Undisclosed
March 06, 2023
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron
Details : Based on this agreement, Eisai will acquire exclusive development and marketing rights from Kyorin for the agent in the said four countries, and will be responsible for submitting a New Drug Application for the agent.
Product Name : Gemtesa
Product Type : Small molecule
Upfront Cash : Undisclosed
March 31, 2021
Reset All
